AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29221791 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 28700473 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 48
Study 28700473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative diuresis
Number of subjects: 48
Study 26120981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (10ml of the solution in one injection once a day in 200 ml of isotonic solution of sodium chloride intravenously in drops in the morning during 10 days)
Number of subjects: 120
Study 26120981 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (nonsteroid anti‐inflammatory drugs, myorelaxants, vitamins)
Number of subjects: 120
Study 23927582 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg/day)
Number of subjects: 182
Study 23927582 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 182
Study 20223273 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-rinse adhesive (Adper Scotchbond 1XT and Filtek Supreme)
Number of subjects: 42
Study 20223273 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Filtek Silorane adhesive and composite)
Number of subjects: 42
Study 18469158 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly epoetin alfa
Number of subjects: 83
Study 18469158 — intervention group
Group type: COMPARATOR
Intervention: Control (twice- or thrice-weekly epoetin alfa)
Number of subjects: 83
Study 17000937 — intervention group
Group type: EXPERIMENTAL
Intervention: Care transitions intervention
Number of subjects: 750
Study 12677616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stimulation infraclavicular brachial plexus block (ICB) with 40 mL of ropivacaine 0.75%
Number of subjects: 100
Study 12677616 — intervention group
Group type: COMPARATOR
Intervention: Triple-stimulation axillary block (AxB) with 40 mL of ropivacaine 0.75%
Number of subjects: 100
Study 12677616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stimulation infraclavicular brachial plexus block (ICB)
Number of subjects: 100
Study 12677616 — intervention group
Group type: COMPARATOR
Intervention: Triple-stimulation axillary block (AxB)
Number of subjects: 100
Study 10898061 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask during CAPD bag exchange
Number of subjects: 64
Study 10898061 — intervention group
Group type: COMPARATOR
Intervention: No face mask during CAPD bag exchange
Number of subjects: 64
Study 8642959 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 5193
Study 8642959 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin derivatives
Number of subjects: 5193
Study 8642959 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with artemisinin derivatives
Number of subjects: 5193
Study 8642959 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of artemisinin derivatives in routine treatment
Number of subjects: 5193
Study 1873424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tilidine-naloxone
Number of subjects: 120
Study 1873424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6313436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography with oil contrast medium
Number of subjects: 121
Study 6313436 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography with aqueous contrast medium
Number of subjects: 121
Study 3896353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine added to cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFPV)
Number of subjects: 427
Study 3896353 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)
Number of subjects: 427
Study 31406274 — intervention group
Group type: EXPERIMENTAL
Intervention: Black smokers
Number of subjects: 366
Study 31406274 — intervention group
Group type: COMPARATOR
Intervention: White smokers
Number of subjects: 366
Study 30196270 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise and gym membership
Number of subjects: 0
Study 30196270 — intervention group
Group type: COMPARATOR
Intervention: Motivational discussions and self-monitoring of PA using fitness trackers
Number of subjects: 0
Study 26377522 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatizing images and text in antiobesity advertisements
Number of subjects: 161
Study 26377522 — intervention group
Group type: COMPARATOR
Intervention: Nonstigmatizing images and text in antiobesity advertisements
Number of subjects: 161
Study 24834504 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + MTZ (400 mg TID)
Number of subjects: 118
Study 24834504 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + MTZ + AMX (500 mg TID)
Number of subjects: 118
Study 24834504 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + CHX (0.12% BID)
Number of subjects: 118
Study 24834504 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 118
Study 23244539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 20
Study 23244539 — intervention group
Group type: COMPARATOR
Intervention: Control pasta
Number of subjects: 20
Study 20637766 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of an Adult formulation (Group HAB_2D: 150; 0‐6 months)
Number of subjects: 300
Study 20637766 — intervention group
Group type: COMPARATOR
Intervention: Three doses of a Paediatric formulation (Group HAB_3D: 150; 0‐1‐6 months)
Number of subjects: 300
Study 18337175 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-potentiating reconstituted influenza virosomes (IRIV) with synthetic malaria peptides
Number of subjects: 16
Study 18337175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing IRIV specific cellular immunity
Number of subjects: 16
Study 18337175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing influenza specific T cell responses
Number of subjects: 16
Study 15734255 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 22
Study 12869356 — intervention group
Group type: EXPERIMENTAL
Intervention: B9340 at 4.5 nmol/min
Number of subjects: 8
Study 12869356 — intervention group
Group type: EXPERIMENTAL
Intervention: B9340 at 13.5 nmol/min
Number of subjects: 8
Study 12869356 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 12869356 — intervention group
Group type: EXPERIMENTAL
Intervention: B9340 (13.5 nmol/min) with bradykinin (100 pmol/min)
Number of subjects: 8
Study 10329034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (400 mg/m2 carboplatin, and 30 mg bleomycin)
Number of subjects: 76
Study 10329034 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized external pelvic radiation therapy
Number of subjects: 76
Study 10329034 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 76
Study 8720288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg daily) and interferon alfa (3 MU thrice weekly) for 6 months
Number of subjects: 30
Study 8720288 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa alone (3 MU thrice weekly) for 6 months
Number of subjects: 30
Study 2025075 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA graft
Number of subjects: 1150
Study 2025075 — intervention group
Group type: COMPARATOR
Intervention: SVG graft
Number of subjects: 1150
Study 7321036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exerciser with electronic counter and visual display
Number of subjects: 12
Study 7321036 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual display of exercises completed
Number of subjects: 12
Study 7321036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Number of subjects: 12
Study 30862999 — intervention group
Group type: COMPARATOR
Intervention: Meal replacement group (MR-G) with soy-yogurt-honey preparation
Number of subjects: 26
Study 30862999 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided lifestyle change group (LC-G) with endurance activity and nutrition counselling
Number of subjects: 26
Study 30113670 — intervention group
Group type: EXPERIMENTAL
Intervention: RNase III cleavage
Number of subjects: 0
Study 26775079 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 220
Study 26775079 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 220
Study 24490645 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing another donor treated for vasovagal symptoms
Number of subjects: 1209
Study 21296862 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF (10 µg/kg/day intravenous infusion once daily for 5 days)
Number of subjects: 40
Study 19774396 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified LRP technique
Number of subjects: 104
Study 19774396 — intervention group
Group type: COMPARATOR
Intervention: Standard LRP technique
Number of subjects: 104
Study 17395566 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic health education program (three sessions)
Number of subjects: 455
Study 17395566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 455
Study 16392976 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 126
Study 16392976 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher for free methadone maintenance treatment (MMT)
Number of subjects: 126
Study 16392976 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management plus voucher
Number of subjects: 126
Study 16392976 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 11179985 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole alone
Number of subjects: 33
Study 11179985 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 33
Study 11179985 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori-negative GERD patients)
Number of subjects: 33
Study 9290166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated for cryptorchidism
Number of subjects: 47
Study 9290166 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 47
Study 8496765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 49
Study 8496765 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 49
Study 8496765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3440773 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (23 mg)
Number of subjects: 69
Study 3440773 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges
Number of subjects: 69
Study 3440773 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo lozenges
Number of subjects: 69
Study 31429599 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol (RV) 330 mg, 3 times a day for 3 days plus an additional 330 mg on the morning of the fourth day.
Number of subjects: 10
Study 31203517 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study 31203517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 0
Study 28946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 38
Study 28946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Number of subjects: 38
Study 28946576 — intervention group
Group type: COMPARATOR
Intervention: Control (breathing and relaxation exercises)
Number of subjects: 38
Study 26119811 — intervention group
Group type: EXPERIMENTAL
Intervention: HENSD (2.5 MJ)
Number of subjects: 23
Study 26119811 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (0.4 MJ)
Number of subjects: 23
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with quinidine 300 mg (n = 42)
Number of subjects: 220
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with verapamil 240 mg (n = 34)
Number of subjects: 220
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with dronedarone 400 mg (n = 34)
Number of subjects: 220
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with amiodarone 400 mg (n = 30)
Number of subjects: 220
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with digoxin 0.25 mg (n = 48)
Number of subjects: 220
Study 23784266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with atorvastatin 80 mg (n = 32)
Number of subjects: 220
Study 21762407 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment in periodontitis patients
Number of subjects: 218
Study 21762407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning in periodontitis patients
Number of subjects: 218
Study 21762407 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis treatment in gingivitis patients
Number of subjects: 218
Study 21762407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning in gingivitis patients
Number of subjects: 218
Study 19356912 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g cod 5 times a week
Number of subjects: 126
Study 19356912 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g cod 3 times a week
Number of subjects: 126
Study 19356912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seafood)
Number of subjects: 126
Study 16797729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and/or adenoidectomy (T&A)
Number of subjects: 101
Study 15523318 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple strategy (stenting the main vessel and balloon dilatation for the side branch)
Number of subjects: 91
Study 15523318 — intervention group
Group type: COMPARATOR
Intervention: Complex strategy (stents for both vessels)
Number of subjects: 91
Study 11517272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg orally)
Number of subjects: 0
Study 11517272 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg, i.v.)
Number of subjects: 0
Study 11517272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9268187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (10,000 anti-factor Xa U/ml with different preservatives)
Number of subjects: 24
Study 9268187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (20,000 anti-factor Xa U/ml)
Number of subjects: 24
Study 9268187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (all formulations)
Number of subjects: 24
Study 9268187 — intervention group
Group type: COMPARATOR
Intervention: Intravenous treatment (control)
Number of subjects: 24
Study 8302307 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 52
Study 8302307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8302307 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 52
Study 3549029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg X kg‐1)
Number of subjects: 160
Study 3549029 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 ml)
Number of subjects: 160
Study 3549029 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (0.05 mg X kg‐1)
Number of subjects: 160
Study 3549029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg X kg‐1)
Number of subjects: 160
Study 30458863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination gefitinib (250 mg daily for 7 days) and methotrexate (50 mg/m2 single dose)
Number of subjects: 328
Study 30458863 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (50 mg/m2 single dose)
Number of subjects: 328
Study 27028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the mathematic model (Group A)
Number of subjects: 103
Study 26589957 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated family case conferencing
Number of subjects: 20
Study 26589957 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 23206333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core biopsy of small renal masses
Number of subjects: 58
Study 22007089 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, interactive patient simulation featuring an Arab American Muslim patient (N=97)
Number of subjects: 199
Study 22007089 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=102)
Number of subjects: 199
Study 18840369 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once a day for 6 days
Number of subjects: 24
Study 18840369 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine 10 mg once a day for 6 days with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6
Number of subjects: 24
Study 18840369 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine 10 mg alone
Number of subjects: 24
Study 18840369 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine 10 mg with azithromycin
Number of subjects: 24
Study 16950473 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT) measurement and vascular age determination
Number of subjects: 506
Study 16950473 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT measurement and vascular age determination
Number of subjects: 506
Study 12875611 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine 2g twice daily
Number of subjects: 84
Study 12875611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 11203866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur in a high‐speed handpiece followed by acid etching
Number of subjects: 48
Study 11203866 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion (27 microns Al2O3) followed by acid etching
Number of subjects: 48
Study 11203866 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion (27 microns Al2O3)
Number of subjects: 48
Study 11203866 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion (50 microns Al2O3)
Number of subjects: 48
Study 11203866 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNO3 staining (for cavities prepared with bur or air abrasion followed by acid etching)
Number of subjects: 48
Study 8026000 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg
Number of subjects: 8
Study 8026000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2657303 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 cm H2O PEEP
Number of subjects: 100
Study 2657303 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 cm H2O PEEP
Number of subjects: 100
Study 2657303 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 cm H2O PEEP
Number of subjects: 100
Study 2657303 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 100
Study 2657303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 100
Study 4938245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine 100 mg in divided dosage
Number of subjects: 6
Study 4938245 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 6
Study 31530074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with radium-223 (Ra-223) and abiraterone acetate plus prednisone or prednisolone (AAP)
Number of subjects: 0
Study 31530074 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate plus prednisone or prednisolone (AAP)
Number of subjects: 0
Study 30460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 160
Study 30460974 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 160
Study 29082651 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine (600 mg/d)
Number of subjects: 190
Study 29082651 — intervention group
Group type: COMPARATOR
Intervention: entecavir (0.5 mg/d)
Number of subjects: 190
Study 25098924 — intervention group
Group type: COMPARATOR
Intervention: 8-week proton pump inhibitor (PPI) therapy with 20 mg of omeprazole for 56 days
Number of subjects: 77
Study 25098924 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week Helicobacter pylori eradication therapy (40 mg of omeprazole, 1,500 mg of amoxicillin, and 800 mg of clarithromycin for 7 days) followed by 7-week rebamipide treatment (300 mg for 49 days)
Number of subjects: 77
Study 23811317 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training program (12-16Hz-4mm; 3 sessions/week for 12 weeks)
Number of subjects: 50
Study 23811317 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 50
Study 23811317 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training program
Number of subjects: 50
Study 21067727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.625 mg) with oral medroxyprogesterone acetate (5 mg) on 14 of the 28 days
Number of subjects: 77
Study 21067727 — intervention group
Group type: COMPARATOR
Intervention: Natural E(2) gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days
Number of subjects: 77
Study 19185243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 8% pH 6.0
Number of subjects: 36
Study 19185243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 8%
Number of subjects: 36
Study 19185243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 16% given 6 times
Number of subjects: 36
Study 19185243 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine 4%, 8%, or 16%
Number of subjects: 36
Study 19185243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17305938 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 30
Study 17305938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 30
Study 17305938 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 30
Study 15217654 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1)‐induced hypotension
Number of subjects: 24